Omeros to Present at the UBS Global Healthcare Conference
May 15 2019 - 7:00AM
Business Wire
Omeros Corporation (NASDAQ: OMER) today announced that Gregory
A. Demopulos, M.D., chairman and chief executive officer, will
present at the UBS Global Healthcare Conference in New York next
week. The presentation is scheduled for Wednesday, May 22, 2019 at
8:00 a.m. EDT.
The presentation will be webcast. The live and archived webcasts
can be accessed on the investor relations page of company’s website
at www.omeros.com.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company
committed to discovering, developing and commercializing
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, complement-mediated
diseases, disorders of the central nervous system and
immune-related diseases, including cancers. The company’s drug
product OMIDRIA® (phenylephrine and ketorolac intraocular solution)
1% / 0.3% is marketed for use during cataract surgery or
intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the European Union,
the European Commission has approved OMIDRIA for use in
cataract surgery and other IOL replacement procedures to maintain
mydriasis (pupil dilation), prevent miosis, and to reduce
postoperative eye pain.
Omeros has multiple Phase 3 and Phase 2 clinical-stage
development programs focused on complement-associated thrombotic
microangiopathies, complement-mediated glomerulonephropathies,
cognitive impairment and addictive and compulsive disorders. In
addition, Omeros has a diverse group of preclinical
programs and a proprietary G protein-coupled receptor (GPCR)
platform through which it controls 54 new GPCR drug targets and
corresponding compounds, a number of which are in preclinical
development. The company also exclusively possesses a novel
antibody-generating platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515005309/en/
Jennifer Cook WilliamsCook Williams Communications, Inc.Investor
and Media Relations360.668.3701jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024